Pacira reports Nov 2022 preliminary net product sales of $57.5M; EXPAREL unit volumes up 4% YoY

Pacira BioSciences, Inc.

EXPAREL net sales $46.0M (99% of Nov 2021); unit volumes 104% of Nov 2021; selling days flat at 20.
ZILRETTA net sales $10.0M; iovera° net sales $1.5M (unchanged YoY).
Expanded contracting and 340B pricing expected to drive volume growth and be accretive in 2023.
No 2022 revenue or gross margin guidance provided due to COVID-19 and labor shortage uncertainty.
Company continues monthly intra-quarter sales reporting until visibility improves.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported the month of November 2022 results: revenue $57.5 million.

Period: the month of November 2022
Revenue: $57.5 million
Result: preliminary results

Exact text from the filing

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of November 2022.

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-22-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.